Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH and ...
Ascendis Pharma AS (ASND) posts EUR366 million in quarterly product revenue, a 42% non-IFRS operating margin, and raises full-year operating cash flow guidance to at least EUR600 million. Related Stocks: ASND ,